Our Products
SpeciaTron™
SpeciaTron™ Division Founded in 2025, the SpeciaTron™ Division of Ytiliga Private Limited is dedicated to delivering speciality pharmaceuticals anchored in a strong patent portfolio and a pipeline of high-impact innovations.
Urology
In 2018, we introduced our urology range marking our first major expansion. This division focuses on addressing various urological conditions with a portfolio of innovative products designed to improve patient outcomes.
NephroTron™
Building on our success in urology, we launched the nephrology range under the division NephroTron™ in 2020. This division is dedicated to providing advanced treatments for kidney-related conditions, leveraging cutting-edge research and technology.
UroOncology
In 2022, we further expanded Urology to include the uro-oncology range. This addition underscores our commitment to addressing complex and critical health issues, providing specialized treatments for cancers of the urinary system.
AndroXprts™
In the first half of 2024, we launched the Andrology vertical under Urology, targeting the previously unaddressed market of andrology. This vertical is backed by innovative research and is focused on providing solutions for male reproductive health.
CNStron™
Continuing our momentum, in the second half of 2024, we introduced the CNStron™ division, dedicated to neurology specialty drugs. This division aims to bring advanced neurological treatments to patients, reflecting our commitment to comprehensive healthcare solutions.